Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

The Lancet Oncology

Volumn 16, Issue 16, 2015, Pages 1605-1616

  Wilkins, Anna ^a   Mossop, Helen ^a   Syndikus, Isabel ^b   Khoo, Vincent ^a,c   Bloomfield, David ^d   Parker, Chris ^c   Logue, John ^e   Scrase, Christopher ^f   Patterson, Helen ^g   Birtle, Alison ^h   Staffurth, John ^i,j   Malik, Zafar ^k   Panades, Miguel ^l   Eswar, Chinnamani ^m   Graham, John ⁿ   Russell, Martin ^o   Kirkbride, Peter ^p   O'Sullivan, Joe M ^q   Gao, Annie ^a   Cruickshank, Clare ^a   Griffin, Clare ^a   Dearnaley, David ^a,c   Hall, Emma ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d Worthing Hospital   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f IPSWICH HOSPITAL   (United Kingdom)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h ROYAL PRESTON HOSPITAL   (United Kingdom)

ⁱ CARDIFF UNIVERSITY   (United Kingdom)

^j VELINDRE CANCER CENTRE   (United Kingdom)

^k WHISTON HOSPITAL   (United Kingdom)

^l LINCOLN COUNTY HOSPITAL   (United Kingdom)

^m Southport General Infirmary   (United Kingdom)

ⁿ MUSGROVE PARK HOSPITAL   (United Kingdom)

^o BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^p SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^q QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; CONVENTIONALLY FRACTIONATED RADIOTHERAPY; EXPANDED PROSTATE CANCER INDEX; FOLLOW UP; FUNCTIONAL ASSESSMENT OF CANCER THERAPY PROSTATE; HISTOPATHOLOGY; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE ASSESSMENT; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SEMINAL VESICLE; SHORT FORM 12; SHORT FORM 36; UNITED KINGDOM; ADVERSE EFFECTS; CLINICAL TRIAL; INTENSITY MODULATED RADIATION THERAPY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROSTATIC NEOPLASMS; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION INJURIES; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; DOSE HYPOFRACTIONATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84951310242     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00280-6     Document Type: Article

References (29)

1. Cancer Research UK Prostate cancer statistics-key facts (accessed June 6 2015). http://info.cancerresearchuk.org/cancerstats/keyfacts/prostate-cancer/.
2. Sonn GA, Sadetsky N, Presti JC, Litwin MS Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol 2013, 189:S59-S65.
3. Litwin MS, Lubeck DP, Henning JM, Carroll PR Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998, 159:1988-1992.
4. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13:43-54.
5. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998, 36:1002-1012.
6. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56:899-905.
7. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997, 50:920-928.
8. Ware J, Kosinski M, Keller SD A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220-233.
9. Szymanski KM, Wei JT, Dunn RL, Sanda MG Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010, 76:1245-1250.
10. Litwin MS, Brook RH, Fink A, Ganz PA, Hays RD, Leake B UCLA postate cancer index (UCLA-PCI) (accessed Oct 14, 2014)]. http://www.proqolid.org/instruments/ucla_prostate_cancer_index_ucla_pci.
11. FACIT administration and scoring guidelines, (accessed Sept 1, 2014). http://www.facit.org/FACITOrg/Questionnaires.
12. FACT-P Scoring Guidelines (Version 4), (accessed Sept 1, 2014). http://www.facit.org/FACITOrg/Questionnaires.
13. Scoring instructions for the expanded prostate cancer index composite (EPIC) (accessed Sept 1, 2014). http://medicine.umich.edu/sites/default/files/content/downloads/Scoring%20Instructions-EPIC.pdf.
14. Scoring Instructions for the Expanded Prostate cancer Index Composite Short Form (EPIC-26) (accessed Sept 1, 2014). http://medicine.umich.edu/sites/default/files/content/downloads/Scoring%20Instructions%20for%20the%20EPIC%2026.pdf.
15. Williams R Generalized ordered logit/partial proportional odds models for ordinal dependent variables. Stata J 2006, 6:58-82.
16. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010, 8:162-200.
17. Jayadevappa R, Malkowicz SB, Wittink M, Wein AJ, Chhatre S Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors. Health Serv Res 2012, 47:1902-1925.
18. Huang GJ, Sadetsky N, Penson DF Health related quality of life for men treated for localized prostate cancer with long-term follow up. J Urol 2010, 183:2206-2212.
19. Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 2015, 16:274-283.
20. Norkus D, Karklelyte A, Engels B, et al. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol 2013, 8:206.
21. Arcangeli G, Fowler J, Gomellini S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 79:1013-1021.
22. Hoffman KE, Voong KR, Pugh TJ, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 2014, 88:1074-1084.
23. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138.
24. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011, 81:1271-1278.
25. Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013, 31:3860-3868.
26. Koontz BF, Bossi A, Cozzarini C, Wiegel T, D'Amico A A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol 2014, 68:683-691.
27. Dearnaley DP, Sydes MR, Langley RE, et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol 2007, 83:31-41.
28. Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys 2010, 77:773-783. for the MRC RT01 collaborators.
29. Martin NE, Massey L, Stowell C, et al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 2014, 67:460-467.